List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers have used a peptide called D6PV to lower triglycerides in mouse models, which could be used as a therapy for high triglyceride-induced acute pancreatitis in humans.
Research has shown that human metapneumovirus uses RNA methylation to hide from the immune system and that knocking out this methylation creates a mutant strain which acts like a vaccine.
The mechanism that prevents destruction of cancer cells by CAR T-cell therapy has been identified by researchers in Pennsylvania.
An innovation using artificial intelligence to analyse developing lung cell developments in vitro revealed what promotes them to develop and allowed researchers to create better quality lung tissue models.
Research determined macrophages’ role in forming a permanent cardiac scar after a heart attack, the researchers suggest altering this behaviour may make the scar temporary and allow restoration of heart function.
Researchers have conducted a genetic screen in mice to discover a family of genes that contributes to the development of Huntington's.
A new study has shown in three dimensions how drugs bind to HIV, which could be used to improve the design of drugs or develop novel therapies.
Research into drug targets for sleeping sickness parasite T. brucei has characterised the inosine-5'-monophosphate dehydrogenase (IMPDH) enzyme, providing a possible novel avenue for therapies.
Research has identified that putrescine, which aids macrophages in clearing dead cells, is lacking in atherosclerosis animal models and could be a potential therapeutic for the condition.
A promising route for tackling the often-fatal MERS-coronavirus (MERS-CoV) has been identified by researchers in Germany.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Scientists have produced hundreds of organoids which they say could be produced on a large-scale as a low-cost tissue model to help research and test new medulloblastoma therapies.
A study has shown that inexpensive nanoparticles can effectively inhibit PD-L1 in cancer cells in the lab and work as well as antibodies, providing a potential alternative immunotherapy.
A study has shown that type II kinase inhibitors targeting CDK8 alone are ineffective because mutations leave them inactive, suggesting future therapies should target CDK8 in complex.
Research demonstrated a complex of palladium and thiosemicarbazone is a more selective and powerful chemotherapeutic than the current standard of care cisplatin.
